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INTRODUCTION
Antiphospholipid syndrome (APS) is a multisystem autoimmune 
disorder characterized by arterial or venous thrombosis and preg-
nancy morbidity in the presence of antiphospholipid antibodies 
(aPL).1 It can be primary or secondary. Primary antiphospholipid syn-
drome occurs in the absence of any other related disease. Secondary 
antiphospholipid syndrome occurs with other autoimmune diseases, 
such as systemic lupus erythematosus. 
The presence of aPL can be demonstrated in one of three ways: 
the presence of anticardiolipin antibodies (aCL), β 2-glycoprotein I 
antibodies (GPI), or lupus anticoagulant antibodies (LA).1 To meet 
classification criteria for antiphospholipid syndrome, patients should 
have one clinical criterion, either vascular thrombosis (venous or 
arterial) or pregnancy morbidity (at least one fetal death or preterm 
delivery or three or more unexplained, consecutive, spontaneous 
pregnancy losses) and one laboratory criterion, the presence of aPL 
antibodies need to be seen twice and at least 12 weeks apart for con-
firmation. Neurological manifestations are common in APS and are 
attributed mainly to vascular thrombosis and aPL-induced neuronal 
tissue injury. The most common neurological presentation is an isch-
emic cerebrovascular accident (CVA) or transient ischemic attack 
(TIA). However, clinical presentations including cognitive dysfunc-
tion, headaches, seizures, and psychosis may be atypical in some cases, 
which makes diagnosis more difficult.2 
In our case, a male patient initially presented with a neurocognitive 
disorder, dementia, cerebral atrophy, and seizure of unknown etiology. 
A diagnosis of APS was made after a brain biopsy revealed microin-
farcts and intimal fibrosis and an aPL antibody test was positive.
CASE REPORT
A 37-year-old male presented to the clinic with an abnormal gait, 
chronic fatigue, muscle stiffness, and cutaneous bruises. He had suf-
fered these symptoms for many years and initially was diagnosed with 
a cerebellar neurodegenerative disease of unknown cause. He had 
seizures and neuropsychiatric symptoms that primarily was repre-
sented with mild cognitive impairment and frequent headaches with 
nonspecific anxiety. Initial brain images revealed atrophy of the brain 
without a clear explanation. 
A physical exam showed significant abnormal gait and muscle 
strength of 4/5 in both the upper and lower extremities. Primary lab 
results revealed acute kidney injury and thrombocytopenia. Hyper-
coagulable panel studies (e.g., protein C, protein S, prothrombin 
gene mutation, and Factor V Leiden) were collected and results were 
unremarkable. A follow-up MRI showed worsening brain atrophy 
secondary to chronic cerebral ischemia, and a brain biopsy showed 
microinfarcts and intimal fibrosis (Figure 1). An underlying autoim-
mune disease was suspected, and the patient’s work-up came back 
with the following results: cardiolipin IgG >100 GPL U/ml (nega-
tive <10 GPL U/ml, strongly positive ≥80 GPL U/ml), β 2-GP1 IgG 
>100 U/ml (positive ≥15 U/ml), aPTT 63 S (normal <40 S), and an 
aPTT-LA mix that remained high. 
The patient met the criteria for antiphospholipid syndrome accord-
ing to the presence of antiphospholipid antibodies in addition to the 
vascular thrombosis, which led to microinfarctions of the brain micro-
circulation that eventually resulted in cerebral and cerebellar atrophy 
and neurocognitive disorder. Treatment was started with aspirin 
81 mg daily, hydroxychloroquine 200 mg twice daily, and warfarin 
with targeted INR (2 - 3). On subsequent visits, the patient reported 
improvement in his headaches, muscle stiffness, and overall general 
condition. Most importantly, since starting treatment, surveillance 
brain imaging has remained stable, and the patient’s renal function 
has improved.
Figure 1. An MRI of the brain showed an increased white matter signal in the 
centrum semiovale representing encephalomalacia. There was generalized 
prominence of the cortical sulci representing diffuse cerebral volume loss. 
DISCUSSION
The incidence of cerebellar CVA is approximately 1.5% with an 
average age of 62 years.3 The main causes are atherosclerosis and 
cardiac emboli. CVA is relatively rare in younger age groups, and a 
thorough evaluation to rule out thromboembolic disease should be 
considered for younger patients. The prevalence of APS with isch-
emic CVA is as high as 22%, and patients with CVAs are 5.48 times 
more likely to have the aPL antibodies than the patients without CVAs 
(95% CI 4.42-6.79).
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Neurological manifestations have been reported due to thrombosis, 
cerebral ischemia, and direct neuronal cell injury by anticardio-
lipin antibodies, which also can lead to neuropsychiatric symptoms 
including headache, migraines, chorea, anxiety, and cognitive 
disorders.4,5 These neurological manifestations may be confused 
with other neurological syndromes. The presence of aPL has strong 
correlations with ischemic CVA, cognitive deficits, and white matter 
lesions;6 furthermore, patients who are β 2-GPI-positive have a 
twofold increased risk of CVA within 15 years of follow-up com-
pared with aCL-negative individuals.7 
The guidelines recommend anticoagulation for secondary pre-
vention.8 Warfarin is the standard of care with INR of 2 - 3. Ongoing 
studies examine the efficacy and safety of direct oral anticoagulants 
in thrombotic APS, especially rivaroxaban, which potentially provides 
an additional benefit to the anticoagulant effect, by limiting comple-
ment activation in APS patients with thrombotic events while they 
are on warfarin. On the other hand, hydroxychloroquine (HCQ) has 
been used in SLE patients, but some studies report that HCQ has a 
very important role in APS patients by decreasing the aPL antibody 
titers, preventing recurrent arterial thrombosis, and inhibiting platelet 
aggregation by inhibiting aPL-induced platelet GPIIb/IIIa receptor 
expression.9,10
Early treatment with anticoagulants and aspirin in those patients 
are crucial to prevent recurrent CVAs and TIAs.9 HCQ has an impor-
tant role to decrease the antibody titers and anti-inflammatory effect. 
Several experimental measures are addressing the immunomodula-
tory mechanism in treatment of anti-phospholipid syndrome, through 
inhibition tissue factor upregulation, which is an important mecha-
nism that explains the pro-thrombotic effects of aPL. These measures 
include tissue factor inhibition, p38 mitogen-activated protein kinase 
inhibition, nuclear factor-kB inhibition, platelet glycoprotein receptor 
inhibition, hydroxychloroquine, statins, inhibition of b2GPI and/or 
anti-b2GPI binding to target cells, complement inhibition, and B cell 
inhibition. Further studies are required for the role of HCQ in second-
ary thrombosis prevention. 
The treatment of recurrent thrombosis is controversial. However, 
the available options are targeting high INR, using direct oral anti-
coagulants, and adding HCQ. The possibility that the INR may not 
reflect the true anticoagulant intensity in APS patients should be 
considered. This is due to the variable responsiveness to LA of the 
reagents used in the INR test, leading to the potential instability of 
anticoagulation. In our case, the patient started on oral anticoagulants 
and aspirin to prevent further transient ischemic attacks (TIAs) and 
CVAs, and that is what kept his brain imaging stable.
CONCLUSIONS
A high suspicion index and a thorough workup for all patients with 
CVA presenting before the age of 50 are warranted. Data on etiolo-
gies and risk factors for young adults with stroke comes from a few 
single center or population-based cohorts.11-13 Vasculopathy (such as 
arterial dissection), cardiac defects, recent pregnancy, other genetic 
hypercoaguable states, smoking and illicit drug use, premature ath-
erosclerosis, hypertension, low physical activity, metabolic disorders, 
and possibly migraine should be on the differential list for such pre-
sentations. APS should be added and included in the differential list 
of diagnoses, especially when the patients present with atypical neu-
rological disorders including cerebellar neurodegenerative disease, 
seizure, and intractable headache.
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